Levotofisopam S-tofisopam: Phase IIa data

Data from 13 patients in an open-label, U.S. Phase IIa trial showed that 50 mg levotofisopam led to a mean percent reduction in sUA from baseline to day 7, the primary endpoint, of 48.8%. On secondary...